Cobra Biologics buys Unitech Pharma Group


To expand capacity and biopharmaceutical service offering

Cobra Biologics, a cGMP contract manufacturer of biopharmaceuticals with plants in Sweden and the UK, has acquired Unitech Pharma Group and its bio-production facility in Matfors near Sundsvall, Sweden.

Under the terms of the agreement, Cobra Biologics will acquire 100% of the shareholding in Unitech Pharma Group, which provides a 600L clinical and commercial microbial GMP production capacity, commercial aseptic fill/finish and lyophilisation capability.

Peter Coleman, chief executive of Cobra, said the purchase ‘significantly enhances’ Cobra’s service offering.

‘This is the first step as a newly independent business in our intention to expand and grow our business, to provide the best possible service for our customers,’ he said.

Cobra now offers cell line development, analytical and process development, GMP production, fill/finish, product release for Phase I, II, III clinical trials and in-market supply.